Last reviewed · How we verify
NCT06942910: ZODIAC
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants With Chronic Kidney Disease and High Proteinuria
Phase 2 trial testing Zibotentan/Dapagliflozin in Chronic Kidney Disease With High Proteinuria in 224 participants. Currently enrolling.
31 July 2026
Quick facts
| Lead sponsor | AstraZeneca |
|---|---|
| Phase | Phase 2 |
| Status | Recruiting now |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | triple |
| Primary purpose | treatment |
| Enrollment | 224 |
| Start date | 7 May 2025 |
| Primary completion | 31 July 2026 |
| Estimated completion | 31 July 2026 |
| Sites | 15 locations across Russia |
Drugs / interventions tested
- Zibotentan/Dapagliflozin — full drug profile →
- Dapagliflozin (DAPAGLIFLOZIN) — full drug profile →
Conditions studied
- Chronic Kidney Disease With High Proteinuria — all drugs for Chronic Kidney Disease With High Proteinuria →
Sponsor
AstraZeneca — full company profile →
Who can join
18 and older, any sex, with Chronic Kidney Disease With High Proteinuria. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
A Study to Investigate the Effects of Zibotentan/Dapagliflozin Combination Compared to Dapagliflozin Alone in Adult Participants with Chronic Kidney Disease and High Proteinuria
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06942910
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Zibotentan/Dapagliflozin
Trials testing the same drug.
- NCT06087835 — Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Partici · Phase 3 · active not recruiting
Other recruiting trials for Chronic Kidney Disease With High Proteinuria
Currently open trials in the same condition.
- NCT06087835 — Study to Investigate Efficacy, Safety, and Tolerability of Zibotentan/Dapagliflozin Compared to Dapagliflozin in Partici · Phase 3 · active not recruiting
Other AstraZeneca trials
Trials by the same sponsor.
- NCT06998095 — Tezepelumab (Tezspire) Regulatory Postmarketing Surveillance in Korea · not yet recruiting
- NCT07431775 — Saphnelo Use in Females of Child-bearing Potential · not yet recruiting
- NCT07516184 — Explore the Diagnostic Value of Bronchodilation Test With Portable Oscillometry in Asthma Diagnosis · NA · not yet recruiting
- NCT07279935 — Osimertinib Combined With Chemotherapy in Patients Who Had Distant Recurrence After Adjuvant Osimertinib for EGFRm Resec · Phase 4 · not yet recruiting
- NCT07279948 — A Single-arm Observational Study to Characterize the Demographic, Clinical Features and Outcomes of a Brazilian Cohort o · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06942910 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by AstraZeneca
- Last refreshed: 17 April 2026
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06942910.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing